Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Recurrent Gliosarcoma: early-phase trial registry

4 of 8 indexed Recurrent Gliosarcoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Recurrent Gliosarcoma: 8 US clinical trials tracked, 4 recruiting.

Recurrent Gliosarcoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 5 of these trials.

Enrollment posture brief

Registry condition recurrent-gliosarcoma

OPEN 4 | RECR 50% | LATE 0 | EARLY 8 | RANK #2176 | SPON 5

Volume-matched condition peers

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Activity, Motor75%Achalasia50%Recurrent Gliosarcoma (this)50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Recurrent Gliosarcoma

Recurrent Gliosarcoma lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Gliosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Gliosarcoma is recruiting above its size-band peers.

    4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Recurrent Gliosarcoma research.

    M.D. Anderson Cancer Center accounts for 5 of 8 trials (62.5%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Recurrent Gliosarcoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 34 among the 8 trials that report a genuine target (sentinel values excluded). 8 of those (100%) plan for fewer than 100 participants.

  4. Recurrent Gliosarcoma research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 22

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2

Top Sponsors

M.D. Anderson Cancer Center 5 trials
University of Michigan Rogel Cancer Center 1 trials
City of Hope Medical Center 1 trials
Mayo Clinic 1 trials

Named interventions

Most-linked intervention names on Recurrent Gliosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Pharmacological Study Other
2 trials
Therapeutic Conventional Surgery Procedure
2 trials
Temozolomide Drug
2 trials
Laboratory Biomarker Analysis Other
2 trials
Pembrolizumab Biological
2 trials
Re-resection (as part of standard of care) Procedure
1 trials
Carboxylesterase-expressing Allogeneic Neural Stem Cells Biological
1 trials
Lonafarnib Drug
1 trials

US sites by state

Facility locations filed on Recurrent Gliosarcoma trials. A trial with sites in several states counts in each.

Texas 5 trials
Minnesota 1 trials
Michigan 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Recurrent Gliosarcoma page

8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Gliosarcoma condition card totals 8 registered trials; most-linked intervention Pharmacological Study; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.